<p>在过去三个月中，5 位分析师对 4D Molecular Therapeutics（纳斯达克：FDMT）发布了评级，展现了从看涨到看跌的广泛观点。</p>
<p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师评估的 12 个月价格目标揭示了进一步的见解，平均目标为 30.0 美元，最高预估为 33.00 美元，最低预估为 26.00 美元。当前平均价格目标较之前的 28.75 美元上升了 4.35%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769608879_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769608879_0.png"/></p>
<h2>理解分析师评级：全面解析</h2>
<p>通过对最近分析师行动的深入分析，4D Molecular Therapeutics 在金融专家中的地位变得清晰。下面的总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>发布</td>
<td>超配</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>维持</td>
<td>买入</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lisa Walter</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超过市场</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>下调</td>
<td>超配</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>上调</td>
<td>买入</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现的变化，频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对 4D Molecular Therapeutics 最近发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师提供全面分析，给出定性评估，范围从 “超过市场” 到 “低于市场”。这些评级反映了对 4D Molecular Therapeutics 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师探讨价格目标的动态，提供对 4D Molecular Therapeutics 股票未来价值的估计。这一研究揭示了分析师预期随时间的变化。</li>
</ul>
<p>为了获取关于 4D Molecular Therapeutics 市场表现的有价值见解，请将这些分析师评估与关键财务指标结合考虑。保持信息灵通，利用我们的评级表做出明智的决策。</p>
<p>随时了解 4D Molecular Therapeutics 的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>探索 4D Molecular Therapeutics：更深入的了解</h2>
<p>4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，专注于使用靶向和进化的 AAV 载体开发产品候选者。它建立了一个基因治疗产品候选者的组合，专注于三个治疗领域：眼科（玻璃体内载体）包括 4D-150、4D-125、4D-110 和 4D-175；心脏病学（静脉载体）包括 4D-710、4D-725；以及肺病学（气雾剂载体）4D-310。</p>
<h3>4D Molecular Therapeutics：财务表现解析</h3>
<p><strong>市值分析：</strong> 该公司的市值高于行业平均水平，反映出其规模庞大和市场认可度强。</p>
<p><strong>积极的收入趋势：</strong> 对 4D Molecular Therapeutics 的财务数据进行 3 个月的审查，揭示了积极的叙述。截止 2025 年 9 月 30 日，该公司实现了 <strong>2900.0%</strong> 的显著收入增长率，展示了顶线收益的显著增加。与同行相比，该公司的增长率高于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> 4D Molecular Therapeutics 的净利润率低于行业平均水平，表明在维持强劲盈利能力方面面临挑战。净利润率为 <strong>-63195.56%</strong>，公司可能在有效成本管理方面面临困难。</p>
<p><strong>股本回报率（ROE）：</strong> 4D Molecular Therapeutics 的 ROE 超出行业基准，达到 <strong>-14.4%</strong>。这表明其财务管理稳健，股东权益资本的使用效率高。</p>
<p><strong>资产回报率（ROA）：</strong> 4D Molecular Therapeutics 的 ROA 低于行业平均水平，表明在有效利用资产方面面临挑战。ROA 为 <strong>-12.67%</strong>，公司可能在从资产中产生最佳回报方面面临困难。</p>
<p><strong>债务管理：</strong> 4D Molecular Therapeutics 的债务与股本比率低于行业平均水平。该比率为 <strong>0.06</strong>，公司对债务融资的依赖较低，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
<h2>分析师评级基础知识</h2>
<p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度对每只股票进行一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
<p>除了他们的评估，一些分析师通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。必须认识到，尽管他们是专业人士，分析师也是人，只能根据他们的信念提供预测。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>在过去三个月中，5 位分析师对 4D Molecular Therapeutics（NASDAQ:FDMT）进行了评级，显示出从看涨到看跌的情绪混合。12 个月的平均目标价为 30.00 美元，比 28.75 美元上涨了 4.35%。分析师的行动包括上调和下调评级，反映了市场状况。该公司的市值高于行业平均水平，报告了 2900% 的收入增长率，尽管面临净利润率为-63195.56% 的挑战。其债务与股本比率为 0.06，表明对债务融资的依赖较小</p>

<p>In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ: FDMT), presenting a wide array of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在过去三个月中，5 位分析师对 4D Molecular Therapeutics（纳斯达克：FDMT）发布了评级，展现了从看涨到看跌的广泛观点。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.0, a high estimate of $33.00, and a low estimate of $26.00. Witnessing a positive shift, the current average has risen by 4.35% from the previous average price target of $28.75.</p>
<div class="lb-trans"><p>分析师评估的 12 个月价格目标揭示了进一步的见解，平均目标为 30.0 美元，最高预估为 33.00 美元，最低预估为 26.00 美元。当前平均价格目标较之前的 28.75 美元上升了 4.35%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769608879_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769608879_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析师评级：全面解析</h2>
</div><p>The standing of 4D Molecular Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的深入分析，4D Molecular Therapeutics 在金融专家中的地位变得清晰。下面的总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lisa Walter</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>发布</td>
<td>超配</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>维持</td>
<td>买入</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lisa Walter</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超过市场</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>下调</td>
<td>超配</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>上调</td>
<td>买入</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 4D Molecular Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of 4D Molecular Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现的变化，频繁更新他们的建议。无论是 “维持”、“上调” 还是 “下调”，都反映了他们对 4D Molecular Therapeutics 最近发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师提供全面分析，给出定性评估，范围从 “超过市场” 到 “低于市场”。这些评级反映了对 4D Molecular Therapeutics 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师探讨价格目标的动态，提供对 4D Molecular Therapeutics 股票未来价值的估计。这一研究揭示了分析师预期随时间的变化。</li>
</ul>
</div><p>For valuable insights into 4D Molecular Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了获取关于 4D Molecular Therapeutics 市场表现的有价值见解，请将这些分析师评估与关键财务指标结合考虑。保持信息灵通，利用我们的评级表做出明智的决策。</p>
</div><p>Stay up to date on 4D Molecular Therapeutics analyst ratings.</p>
<div class="lb-trans"><p>随时了解 4D Molecular Therapeutics 的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>Discovering 4D Molecular Therapeutics: A Closer Look</h2>
<div class="lb-trans"><h2>探索 4D Molecular Therapeutics：更深入的了解</h2>
</div><p>4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，专注于使用靶向和进化的 AAV 载体开发产品候选者。它建立了一个基因治疗产品候选者的组合，专注于三个治疗领域：眼科（玻璃体内载体）包括 4D-150、4D-125、4D-110 和 4D-175；心脏病学（静脉载体）包括 4D-710、4D-725；以及肺病学（气雾剂载体）4D-310。</p>
</div><h3>4D Molecular Therapeutics: Financial Performance Dissected</h3>
<div class="lb-trans"><h3>4D Molecular Therapeutics：财务表现解析</h3>
</div><p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值高于行业平均水平，反映出其规模庞大和市场认可度强。</p>
</div><p><strong>Positive Revenue Trend:</strong> Examining 4D Molecular Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>2900.0%</strong> as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>积极的收入趋势：</strong> 对 4D Molecular Therapeutics 的财务数据进行 3 个月的审查，揭示了积极的叙述。截止 2025 年 9 月 30 日，该公司实现了 <strong>2900.0%</strong> 的显著收入增长率，展示了顶线收益的显著增加。与同行相比，该公司的增长率高于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> 4D Molecular Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-63195.56%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 4D Molecular Therapeutics 的净利润率低于行业平均水平，表明在维持强劲盈利能力方面面临挑战。净利润率为 <strong>-63195.56%</strong>，公司可能在有效成本管理方面面临困难。</p>
</div><p><strong>Return on Equity (ROE):</strong> 4D Molecular Therapeutics's ROE excels beyond industry benchmarks, reaching <strong>-14.4%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 4D Molecular Therapeutics 的 ROE 超出行业基准，达到 <strong>-14.4%</strong>。这表明其财务管理稳健，股东权益资本的使用效率高。</p>
</div><p><strong>Return on Assets (ROA):</strong> 4D Molecular Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-12.67%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 4D Molecular Therapeutics 的 ROA 低于行业平均水平，表明在有效利用资产方面面临挑战。ROA 为 <strong>-12.67%</strong>，公司可能在从资产中产生最佳回报方面面临困难。</p>
</div><p><strong>Debt Management:</strong> 4D Molecular Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.06</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 4D Molecular Therapeutics 的债务与股本比率低于行业平均水平。该比率为 <strong>0.06</strong>，公司对债务融资的依赖较低，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析师评级基础知识</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度对每只股票进行一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他们的评估，一些分析师通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。必须认识到，尽管他们是专业人士，分析师也是人，只能根据他们的信念提供预测。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)

benzinga_article

标普全球医疗股指数 ETF - iShares

4D Molecular Therapeutics

Invesco Nasdaq Biotechnology ETF

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

动态生物技术与基因组 ETF - Invesco

美国制药 ETF - iShares

医疗业 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

医药突破 ETF - ALPS

深入分析 4D Molecular Therapeutics 股票：分析师观点（5 项评级）